Phathom Pharmaceuticals Inc (PHAT)

$11.87 -1.18 (-9.04%)
Market Cap 1.04B
Revenue (ttm) 175.11M
Net Income (ttm) -221.25M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -126.35%
Debt to Equity Ratio -0.49
Volume 1,111,100
Avg Vol 1,236,652
Day's Range N/A - N/A
Shares Out 79.76M
Stochastic %K 7%
Beta 0.57
Analysts Strong Sell
Price Target $23.70

Company Profile

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for t...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 742 8466
Address:
100 Campus Drive, Suite 102, Florham Park, United States
fgggggggg
fgggggggg May. 15 at 7:56 PM
$PHAT These deep downward moves are always followed by giant upward moves. We've seen this movie and playbook over and over -- this was predictable especially with options. I like the analogy of this being like a game of hungry hippo. Very accurate. See you all at $20!
0 · Reply
longshot45
longshot45 May. 15 at 7:42 PM
$PHAT Todays 13Fs looking very strong indeed. Goldman upped position by another 230k shares, Geode 250K, Blackrock 500k. I see some smaller players selling a bit, but the major owners are buying even more. Tells me very good things are ahead. It’s like watching a game of hungry hippos 200 more shares for me. Maybe more if they push back into the 11s
1 · Reply
StardustTrader
StardustTrader May. 15 at 5:07 PM
$PHAT riding the weekly 50. Downside should be to 10.50s, upside is still 30s+. Easy r/r
0 · Reply
Morrito23
Morrito23 May. 15 at 4:16 PM
$PHAT Nibbled a little more just now. Also sold some other shares and waiting for those funds to settle to buy more on Monday. About 10k waiting to be reallocated here.
1 · Reply
Withermania
Withermania May. 15 at 3:58 PM
$PHAT NO volume. Buy the dip.
1 · Reply
fgggggggg
fgggggggg May. 15 at 3:24 PM
$PHAT THIS IS FREE MONEY IF YOU HAVE ANY AVAILABLE. This will be $20 before you know it. Don't be a dope
0 · Reply
fgggggggg
fgggggggg May. 15 at 2:48 PM
$PHAT Don't be stupid, we all know what is happening
0 · Reply
Joe_90_
Joe_90_ May. 15 at 2:17 PM
$PHAT get yr pencil lead ready for when the options expire, usual friday game, same playbook
1 · Reply
fgggggggg
fgggggggg May. 15 at 1:44 PM
$PHAT BULLISH AF
0 · Reply
Withermania
Withermania May. 14 at 9:36 PM
$PHAT tick tock tick tock.
0 · Reply
Latest News on PHAT
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

May 1, 2026, 8:00 AM EDT - 14 days ago

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

Phathom Pharmaceuticals reports Q1 non-GAAP EPS (18c), consensus (19c)

2026-04-30T12:05:31.000Z - 15 days ago

Phathom Pharmaceuticals reports Q1 non-GAAP EPS (18c), consensus (19c)

Phathom Pharmaceuticals still sees 2026 revenue $320M-$34M, consensus $332.04M

2026-04-30T12:02:20.000Z - 15 days ago

Phathom Pharmaceuticals still sees 2026 revenue $320M-$34M, consensus $332.04M

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 15 days ago

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2026

Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 30, 2026, 6:59 AM EDT - 15 days ago

Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Apr 20, 2026, 8:00 AM EDT - 25 days ago

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Phathom Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 15, 2026, 1:30 PM EDT - 4 weeks ago

Phathom Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Apr 6, 2026, 8:00 AM EDT - 5 weeks ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays

2026-03-27T09:00:23.000Z - 7 weeks ago

Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays

Phathom Pharmaceuticals management to meet with Cantor

2026-03-23T18:25:38.000Z - 7 weeks ago

Phathom Pharmaceuticals management to meet with Cantor

Phathom Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 3:30 PM EDT - 2 months ago

Phathom Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Phathom Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 10:30 AM EST - 2 months ago

Phathom Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Phathom Pharmaceuticals price target raised to $25 from $20 at Guggenheim

2026-02-27T12:39:13.000Z - 2 months ago

Phathom Pharmaceuticals price target raised to $25 from $20 at Guggenheim

Phathom Pharmaceuticals price target raised to $13 from $12 at Goldman Sachs

2026-02-26T23:40:20.000Z - 2 months ago

Phathom Pharmaceuticals price target raised to $13 from $12 at Goldman Sachs

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 2 months ago

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2025

Phathom Pharmaceuticals reports Q4 EPS (8c), consensus (19c)

2026-02-26T12:06:11.000Z - 2 months ago

Phathom Pharmaceuticals reports Q4 EPS (8c), consensus (19c)

Phathom Pharmaceuticals sees FY26 net revenues $320M9$345M, consensus $312.56M

2026-02-26T12:05:14.000Z - 2 months ago

Phathom Pharmaceuticals sees FY26 net revenues $320M9$345M, consensus $312.56M

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Feb 26, 2026, 7:00 AM EST - 2 months ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

Feb 17, 2026, 8:00 AM EST - 3 months ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

Phathom Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 11:30 AM EST - 3 months ago

Phathom Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

Feb 5, 2026, 8:00 AM EST - 3 months ago

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

Phathom Pharmaceuticals 6.875M share Secondary priced at $16.00

2026-01-08T11:31:01.000Z - 4 months ago

Phathom Pharmaceuticals 6.875M share Secondary priced at $16.00

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

Jan 7, 2026, 10:33 PM EST - 4 months ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

Phathom Pharmaceuticals announces common stock offering, no amount given

2026-01-07T21:10:45.000Z - 4 months ago

Phathom Pharmaceuticals announces common stock offering, no amount given

Phathom Pharmaceuticals files automatic mixed securities shelf

2026-01-07T21:05:43.000Z - 4 months ago

Phathom Pharmaceuticals files automatic mixed securities shelf

Phathom Pharmaceuticals sees Q4 revenue $57M-$58M, consensus $56.16M

2026-01-07T21:05:23.000Z - 4 months ago

Phathom Pharmaceuticals sees Q4 revenue $57M-$58M, consensus $56.16M

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 7, 2026, 4:05 PM EST - 4 months ago

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Jan 7, 2026, 4:01 PM EST - 4 months ago

Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Phathom Pharmaceuticals initiated with a Strong Buy at Raymond James

2025-12-11T21:16:52.000Z - 5 months ago

Phathom Pharmaceuticals initiated with a Strong Buy at Raymond James

Phathom Pharmaceuticals initiated with an Equal Weight at Barclays

2025-12-08T21:30:59.000Z - 5 months ago

Phathom Pharmaceuticals initiated with an Equal Weight at Barclays

Phathom Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 3:25 PM EST - 5 months ago

Phathom Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Phathom Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 9:30 AM EST - 6 months ago

Phathom Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Phathom Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 4:40 PM EST - 6 months ago

Phathom Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Phathom Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 3:00 PM EST - 6 months ago

Phathom Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Phathom announces first patient dosed in Phase 2 pHalcon-EoE-201 trial

2025-11-04T13:16:14.000Z - 6 months ago

Phathom announces first patient dosed in Phase 2 pHalcon-EoE-201 trial

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Nov 4, 2025, 8:00 AM EST - 6 months ago

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Phathom Pharmaceuticals price target raised to $22 from $17 at Craig-Hallum

2025-10-31T13:31:53.000Z - 7 months ago

Phathom Pharmaceuticals price target raised to $22 from $17 at Craig-Hallum

Phathom Pharmaceuticals Earnings Call Transcript: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 7 months ago

Phathom Pharmaceuticals Earnings Call Transcript: Q3 2025

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 30, 2025, 7:00 AM EDT - 7 months ago

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Oct 25, 2025, 9:59 AM EDT - 7 months ago

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

Oct 23, 2025, 8:00 AM EDT - 7 months ago

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

Oct 20, 2025, 8:00 AM EDT - 7 months ago

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

Oct 6, 2025, 8:00 AM EDT - 7 months ago

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

Phathom Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 1:00 PM EDT - 8 months ago

Phathom Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Phathom Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 9:10 AM EDT - 9 months ago

Phathom Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing

Aug 20, 2025, 8:00 AM EDT - 9 months ago

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing

Phathom Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Phathom Pharmaceuticals Earnings Call Transcript: Q2 2025

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 6:59 AM EDT - 10 months ago

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Jul 28, 2025, 8:00 AM EDT - 10 months ago

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 23, 2025, 4:15 PM EDT - 11 months ago

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

Jun 23, 2025, 7:59 AM EDT - 11 months ago

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

Jun 16, 2025, 8:00 AM EDT - 11 months ago

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

Phathom Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 11, 2025, 10:40 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

Jun 6, 2025, 12:27 PM EDT - 1 year ago

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 9:55 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Phathom Pharmaceuticals Transcript: AGM 2025

Jun 3, 2025, 11:30 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: AGM 2025

Phathom Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 4:00 PM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2025

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 7:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ITCI

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

Apr 28, 2025, 7:59 AM EDT - 1 year ago

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

Frazier Life Sciences Appoints Aditya Kohli to Partner

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Frazier Life Sciences Appoints Aditya Kohli to Partner

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

CDTX

Phathom Pharmaceuticals Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 8, 2025, 10:15 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: 24th Annual Needham Virtual Healthcare Conference

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Phathom Pharmaceuticals Announces Leadership Succession

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces Leadership Succession

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

Mar 31, 2025, 7:59 AM EDT - 1 year ago

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2024

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 6, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Feb 24, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Phathom Pharmaceuticals Transcript: Guggenheim SMID Cap Biotech Conference

Feb 6, 2025, 10:00 AM EST - 1 year ago

Phathom Pharmaceuticals Transcript: Guggenheim SMID Cap Biotech Conference

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Jan 29, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Dec 11, 2024, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Phathom Pharmaceuticals Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 3, 2024, 2:10 PM EST - 1 year ago

Phathom Pharmaceuticals Transcript: 7th Annual Evercore ISI HealthCONx Conference

Phathom Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 1:15 PM EST - 1 year ago

Phathom Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Phathom Pharmaceuticals Transcript: Guggenheim’s Inaugural Healthcare Innovation Conference

Nov 12, 2024, 9:30 AM EST - 1 year ago

Phathom Pharmaceuticals Transcript: Guggenheim’s Inaugural Healthcare Innovation Conference

Phathom Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q3 2024

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Oct 27, 2024, 12:00 PM EDT - 1 year ago

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Phathom Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 12:00 PM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Phathom Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q2 2024

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

Jul 18, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

Phathom Pharmaceuticals Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 11, 2024, 2:40 PM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference

Jun 5, 2024, 12:30 PM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference

Phathom Pharmaceuticals Transcript: AGM 2024

May 23, 2024, 10:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: AGM 2024

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2024

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Phathom Pharmaceuticals Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 10, 2024, 9:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: 23rd Annual Needham Virtual Healthcare Conference

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2023

Mar 7, 2024, 8:30 AM EST - 2 years ago

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2023

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 7, 2024, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

Feb 29, 2024, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

Phathom Pharmaceuticals Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Feb 7, 2024, 1:30 PM EST - 2 years ago

Phathom Pharmaceuticals Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

Dec 6, 2023, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

Phathom Pharmaceuticals Transcript: 6th Annual ISI HealthCONx Conference

Nov 29, 2023, 4:15 PM EST - 2 years ago

Phathom Pharmaceuticals Transcript: 6th Annual ISI HealthCONx Conference

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

Nov 28, 2023, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates

Nov 9, 2023, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates

fgggggggg
fgggggggg May. 15 at 7:56 PM
$PHAT These deep downward moves are always followed by giant upward moves. We've seen this movie and playbook over and over -- this was predictable especially with options. I like the analogy of this being like a game of hungry hippo. Very accurate. See you all at $20!
0 · Reply
longshot45
longshot45 May. 15 at 7:42 PM
$PHAT Todays 13Fs looking very strong indeed. Goldman upped position by another 230k shares, Geode 250K, Blackrock 500k. I see some smaller players selling a bit, but the major owners are buying even more. Tells me very good things are ahead. It’s like watching a game of hungry hippos 200 more shares for me. Maybe more if they push back into the 11s
1 · Reply
StardustTrader
StardustTrader May. 15 at 5:07 PM
$PHAT riding the weekly 50. Downside should be to 10.50s, upside is still 30s+. Easy r/r
0 · Reply
Morrito23
Morrito23 May. 15 at 4:16 PM
$PHAT Nibbled a little more just now. Also sold some other shares and waiting for those funds to settle to buy more on Monday. About 10k waiting to be reallocated here.
1 · Reply
Withermania
Withermania May. 15 at 3:58 PM
$PHAT NO volume. Buy the dip.
1 · Reply
fgggggggg
fgggggggg May. 15 at 3:24 PM
$PHAT THIS IS FREE MONEY IF YOU HAVE ANY AVAILABLE. This will be $20 before you know it. Don't be a dope
0 · Reply
fgggggggg
fgggggggg May. 15 at 2:48 PM
$PHAT Don't be stupid, we all know what is happening
0 · Reply
Joe_90_
Joe_90_ May. 15 at 2:17 PM
$PHAT get yr pencil lead ready for when the options expire, usual friday game, same playbook
1 · Reply
fgggggggg
fgggggggg May. 15 at 1:44 PM
$PHAT BULLISH AF
0 · Reply
Withermania
Withermania May. 14 at 9:36 PM
$PHAT tick tock tick tock.
0 · Reply
ollie999
ollie999 May. 14 at 7:58 PM
$PHAT fine I’ll buy in
2 · Reply
fgggggggg
fgggggggg May. 14 at 7:39 PM
$PHAT DIAMOND HANDS 💎
0 · Reply
TheFlyingDutchmann
TheFlyingDutchmann May. 14 at 7:36 PM
$PHAT loving this. Hidden gem 💎
0 · Reply
Ecryder
Ecryder May. 14 at 7:34 PM
$PHAT
0 · Reply
Morrito23
Morrito23 May. 14 at 7:08 PM
$PHAT Our $15 open contracts doubled since last time I commented on them. Let’s see if they push it above it by tomorrow.
0 · Reply
fgggggggg
fgggggggg May. 14 at 6:32 PM
$PHAT Weird... BULLISH AF
3 · Reply
Joe_90_
Joe_90_ May. 14 at 6:18 PM
$PHAT 13
0 · Reply
fgggggggg
fgggggggg May. 14 at 3:27 PM
$PHAT this thing is on fake trading cruise control. Don't be a dope, you should know what is happening... BULLISH AF!
0 · Reply
fgggggggg
fgggggggg May. 14 at 1:35 PM
$PHAT I’d recommend digging into the 13Fs to see some of the additions to holdings
1 · Reply
fgggggggg
fgggggggg May. 14 at 12:21 PM
$PHAT the fake trading will continue today and tomorrow at a minimum. Don’t be a dope, you should know what is happening. If you feel like you’re losing patience, close your computer and go do something fun. This is going to be one valuable franchise
0 · Reply
longshot45
longshot45 May. 13 at 6:32 PM
$PHAT Have you all voted your shares yet? Didnt see anything crazy on the proxy, but was just wondering. I think the handful of us on here actually own quite a lot and could impact the vote if anything odd was ever proposed
2 · Reply
fgggggggg
fgggggggg May. 13 at 5:11 PM
$PHAT Not sure whether to put on Stairway to Heaven or Bohemian Rhapsody. BULLISH AF!
1 · Reply